Galectin (GALT) director awarded 60,000 stock options at $3.04 strike

Rhea-AI Filing Summary

Galectin Therapeutics Inc. director Richard A. Zordani Jr. reported a grant of stock options on common shares. On January 16, 2026, he received 60,000 stock options with an exercise price of $3.04 per share, issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

The options vest 100% on December 31, 2026, meaning they become fully exercisable on that date. Following this grant, Zordani beneficially owns 60,000 derivative securities directly in the form of these options, providing potential future ownership of the same number of Galectin common shares if exercised.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zordani Richard A. Jr.

(Last) (First) (Middle)

4960 PEACHTREE INDUSTRIAL BLVD

SUITE 240

(Street)

NORCROSS GA 30071

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)(1)	$3.04	01/16/2026		A		60,000		(2)	01/16/2036	Common Stock	60,000	$0	60,000	D

Explanation of Responses:

1. The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

2. The options vest 100% on December 31, 2026.

	Jack W. Callicutt, by power of attorney	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Galectin Therapeutics (GALT) report?

Galectin Therapeutics reported that director Richard A. Zordani Jr. was granted 60,000 stock options on January 16, 2026, as disclosed in a Form 4.

What are the key terms of the 60,000 stock options granted to the Galectin (GALT) director?

The options are a stock option (right to buy) Galectin common stock at an exercise price of $3.04 per share, with a total of 60,000 options granted.

When do the Galectin Therapeutics (GALT) options granted to Richard A. Zordani Jr. vest?

The filing states that the 60,000 stock options vest 100% on December 31, 2026, at which point they become fully exercisable.

Under which plan were the Galectin Therapeutics (GALT) options issued?

The Form 4 states that the stock options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

How many Galectin (GALT) derivative securities does the director own after this transaction?

After the reported grant, Richard A. Zordani Jr. beneficially owns 60,000 derivative securities, all held directly in the form of these stock options.

Is the reported Galectin Therapeutics (GALT) Form 4 transaction a purchase or a grant?

The transaction code is A, and the description shows a grant of stock options at a price of $0 per option, indicating an award rather than an open-market purchase.